Growth Prospects of the Dyskinesia-Pipeline Review, H2 2016

Dyskinesia-Pipeline Review, H2 2016 ​is a new market research publication announced by Reportstack. This report provides an overview of the Dyskinesia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Dyskinesia, complete with analysis by stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dyskinesia and features dormant and discontinued projects.

Complete report available @ Dyskinesia-Pipeline Review, H2 2016

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Dyskinesia
- The report reviews pipeline therapeutics for Dyskinesia by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report reviews key players involved Dyskinesia therapeutics and enlists all their major and minor projects
- The report assesses Dyskinesia therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Dyskinesia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Dyskinesia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned

Adamas Pharmaceuticals, Inc. Addex Therapeutics Ltd Advicenne Astraea Therapeutics, LLC Bionomics Limited Catalyst Biosciences, Inc. Catalyst Pharmaceuticals, Inc. Clevexel Pharma SAS Contera Pharma ApS EpiVax, Inc. Heptares Therapeutics Limited Hua Medicine (Shanghai) Ltd. Integrative Research Laboratories Sweden AB Ipsen S.A. Merz Pharma GmbH & Co. KgaA MitoDys Therapeutics Limited Neurim Pharmaceuticals Ltd Neurocrine Biosciences, Inc. Neurolixis Inc. Osmotica Pharmaceutical Corp. Otsuka Holdings Co., Ltd. Phenomenome Discoveries, Inc. Revance Therapeutics, Inc. Sage Therapeutics, Inc. SciFluor Life Sciences, LLC SOM Innovation Biotech SL Synchroneuron Inc. Teva Pharmaceutical Industries Ltd.

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###